Entropy Neurodynamics reports compelling Phase 2a results showing oral psilocybin dramatically reduces binge eating episodes and related psychiatric symptoms, supporting advancement of its lead IV psilocin candidate.
- 80% sustained reduction in binge-eating episodes across all evaluable patients
- Severe Binge Eating Disorder eliminated by Week 6 post-treatment
- Secondary benefits include reduced anxiety, depression, and psychological inflexibility
- 80% of patients showed waist circumference reduction, suggesting metabolic impact
- Results validate lead asset TRP-8803’s clinical rationale and support ongoing trials
A Breakthrough in Binge Eating Disorder Treatment
Entropy Neurodynamics Limited (ASX – ENP) has unveiled promising Phase 2a clinical trial results for its oral psilocybin candidate, TRP-8802, targeting Binge Eating Disorder (BED). Conducted at the University of Florida and published in the Journal of Eating Disorders, the study demonstrated a rapid and sustained 80% reduction in binge-eating episodes among all evaluable patients, with benefits persisting through a 14-week follow-up.
This milestone not only highlights the potential of psychedelic-assisted therapy in addressing BED but also validates the therapeutic rationale behind Entropy’s lead drug candidate, TRP-8803, an intravenous formulation of psilocin designed for more precise dosing and improved treatment control.
Clinical Trial Insights and Secondary Benefits
The Phase 2a trial enrolled six patients, with five completing evaluation. Remarkably, severe BED cases dropped from 40% at baseline to zero by Week 6, and by Week 14, 80% of participants were classified as having none-to-mild BED. Beyond behavioural improvements, patients experienced notable reductions in anxiety, depression, and psychological inflexibility; key psychiatric drivers of BED.
Metabolic markers also improved, with 80% of patients recording waist circumference reductions at six weeks post-treatment, including two individuals with decreases exceeding 6cm. Exploratory neuroimaging further suggested enhanced cognitive control and neural network reorganisation, aligning with improved regulation of compulsive eating behaviours.
Positioning TRP-8803 in the Therapeutic Landscape
Entropy’s CEO, Jason Carroll, emphasised the distinct advantage of their approach compared to current obesity treatments like GLP-1 therapies, which primarily focus on weight loss without addressing the psychiatric underpinnings of BED. TRP-8803 aims to treat compulsive eating alongside mood and cognitive factors, potentially offering a more holistic and durable solution.
The ongoing trial with Swinburne University is set to further evaluate TRP-8803’s precision dosing, safety, and scalability, building on the encouraging data from the oral psilocybin study. The company’s strategy to combine psychedelic therapy with structured clinical support could redefine treatment paradigms for BED and related neuropsychiatric conditions.
Looking Ahead
While the sample size remains small and longer-term data are pending, these findings mark a significant step forward in psychedelic medicine’s application to eating disorders. Entropy Neurodynamics is poised to advance its clinical programs, potentially reshaping how compulsive eating and its psychiatric drivers are treated in the future.
Bottom Line?
Entropy’s Phase 2a success sets the stage for TRP-8803 to challenge current BED treatments by targeting root psychiatric causes.
Questions in the middle?
- Will larger, controlled trials confirm the durability and safety of TRP-8803’s therapeutic effects?
- How will TRP-8803 integrate or compete with existing GLP-1 obesity therapies in clinical practice?
- What regulatory hurdles remain for psychedelic-assisted therapies targeting BED and related disorders?